ClinicalTrials.gg
RecruitingNCT07049653ROSEUpdated Sep 18, 2026

Anifrolumab Pregnancy Study

An observational study in Systemic Lupus Erythematosus, sponsored by AstraZeneca. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by AstraZeneca · Observational

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
500
Ages
18 Years to 130 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Lupus Erythematosus, Systemic by AstraZeneca — 19 open to participants now, 25 under way, 6 of them phase 3. Lupus Erythematosus, Systemic · AstraZeneca.

Planned enrollment
10th of 19
500 · median 500
Started
2026
with 9 others
Observational
19 of 46
9 open now
Primary completion
2030-12
later than 18 of 24 live
Registered
37th of 46
by date

Among the 46 studies in Lupus Erythematosus, Systemic by AstraZeneca, this one is the 10th largest by planned enrollment of the 19 observational ones that give a count, is one of 10 that started in 2026, is one of 19 observational ones, reaches primary completion later than 18 of the 24 other live ones, and was the 37th registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

19 of the 46 studies in Lupus Erythematosus, Systemic by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 130 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Lupus Erythematosus, Systemic by AstraZeneca, or all of them as a file.
02

Study summary

This is a non-interventional multi-database post-authorisation study to assess pregnancy-related safety data from women with SLE exposed to Anifrolumab.

Read the detailed description

The aim of this study is to describe congenital malformations, adverse pregnancy and birth outcomes in pregnancies/offspring from women with moderate/severe SLE exposed to anifrolumab during pregnancy and to compare with outcomes in women with moderate/severe SLE who are exposed to other standard of care but not anifrolumab. Adverse outcomes related to infant growth up to one year of age will also be investigated.

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • pregnancy, anifrolumab, SLE
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The population will encompass women with SLE of child-bearing potential age (15-49 years old) who start anifrolumab or other selected SLE treatments.

For the safety outcomes analyses the study population will include pregnant women and their infant born anytime during the study period.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women with a continuous enrolment in the database for ≥ 12 months prior to LMP2
  • Women diagnosed with SLE before pregnancy
  • Women exposed to anifrolumab (polytherapy, added to SLE SOC) during pregnancy and/or 16-week period prior to LMP2

Exclusion criteria

Exclusion criteria for EXPOSED SOURCE POPULATION:

- Pregnancies whose date of conception cannot be established

Inclusion criteria for UNEXPOSED SOURCE POPULATION:

  • Women with a continuous enrolment in the database for ≥ 12 months prior to LMP2
  • Women diagnosed with SLE before pregnancy
  • Women treated with SLE SOC during pregnancy

Exclusion criteria for UNEXPOSED SOURCE POPULATION:

  • Women treated with anifrolumab during pregnancy and/or 16-week period prior to LMP2
  • Pregnancies whose date of conception cannot be established

Inclusion criteria for EXPOSED and UNEXPOSED STUDY POPULATION:

- Women with moderate/severe SLE

Exclusion criteria for EXPOSED and UNEXPOSED STUDY POPULATION:

  • Women with a history of CM or chromosomal abnormalities (according to available records), before delivery
  • Women prescribed a confirmed teratogenic drug prior to LMP2 with a time period of 5-half-lives of relevant drug or during pregnancy
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Exposed cohort

    Pregnant individuals with a diagnosis of SLE who are exposed to anifrolumab at any time during pregnancy

  • Unexposed cohort

    Pregnant individuals with a diagnosis of moderate/severe SLE who are not exposed to anifrolumab at any time during pregnancy but who are exposed to other products for the treatment of SLE

06

What researchers measure

Primary outcomes

  1. Risk of major congenital malformations (MCM)

    Describe and estimate the risk of MCM in live and non-live offspring from the women who had moderate/severe SLE and were exposed to anifrolumab during the first trimester of pregnancy or exposed to SOC and unexposed to anifrolumab during the first trimester of pregnancy

    Time frame: From date of conception (DOC) to pregnancy outcome for fetal losses or 12 months of infant age for live births

  2. Relative risk of MCM

    Estimate the relative risk of MCM in live and non-live offspring from the women who had moderate/severe SLE and were exposed to anifrolumab during the first trimester of pregnancy or exposed to SOC and unexposed to anifrolumab during the first trimester of pregnancy

    Time frame: From date of conception (DOC) to pregnancy outcome for fetal losses or 12 months of infant age for live births

  3. Risk of select pregnancy loss outcomes

    Describe and estimate the risk of select pregnancy loss outcomes (composite of spontaneous abortion and stillbirth) in all pregnancies from women who had moderate/severe SLE and were exposed or unexposed to anifrolumab during pregnancy

    Time frame: At delivery/birth

  4. Relative risk of select pregnancy loss outcomes

    Estimate the relative risk of select pregnancy loss outcomes (composite of spontaneous abortion and stillbirth) in pregnancies from women who had moderate/severe SLE and were exposed or unexposed to anifrolumab during pregnancy

    Time frame: At delivery/birth

Secondary outcomes

  1. Demographic and clinical characteristics

    Describe the demographic and clinical characteristics of the live and non-live offspring and their mothers who had moderate/severe SLE and were exposed or unexposed to anifrolumab during the first trimester of pregnancy or anytime during pregnancy

    Time frame: From date of conception (DOC) to pregnancy outcome for fetal losses or 12 months of infant age for live births

  2. Risk of minor congenital malformations (mCM)

    Describe and estimate the risk of mCM in live and non-live offspring from women with moderate/severe SLE who were exposed or unexposed to anifrolumab during pregnancy

    Time frame: From date of conception (DOC) to pregnancy outcome for fetal losses or 12 months of infant age for live births

  3. Relative risk of mCM

    Estimate the relative risk of mCM in live and non-live offspring from women who had moderate/severe SLE and were exposed or unexposed to anifrolumab during pregnancy

    Time frame: From date of conception (DOC) to pregnancy outcome for fetal losses or 12 months of infant age for live births

  4. Risk of adverse pregnancy outcomes

    Describe and estimate the risk of adverse pregnancy outcomes (ectopic pregnancy, spontaneous abortion, elective termination of pregnancy, stillbirth, infections requiring hospitalisation during pregnancy, emergency caesarean section) in all pregnancies from women who had moderate/severe SLE and were exposed or unexposed to anifrolumab during pregnancy

    Time frame: At delivery/birth

  5. Relative risk of adverse pregnancy outcomes

    Estimate the relative risk of adverse pregnancy outcomes (ectopic pregnancy, spontaneous abortion, elective termination of pregnancy, stillbirth, infections requiring hospitalisation during pregnancy, emergency caesarean section) in pregnancies from women who had moderate/severe SLE and were exposed or unexposed to anifrolumab during pregnancy

    Time frame: At delivery/birth

  6. Risk of adverse birth outcomes

    Describe and estimate the risk of adverse birth outcomes (preterm birth, small for gestational age (SGA)) in live offspring from women who had moderate/severe SLE and were exposed or unexposed to anifrolumab during pregnancy

    Time frame: At delivery/birth

  7. Relative risk of adverse birth outcomes

    Estimate the relative risk of adverse birth outcomes (preterm birth, small for gestational age (SGA)) in live offspring from women who had moderate/severe SLE and were exposed or unexposed to anifrolumab during pregnancy

    Time frame: At delivery/birth

07

Study locations

1 of 1 sites recruiting
  • Research Site
    Cary, North Carolina 27513, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Dec 2030, 54 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2025
First posted
Jul 3, 2025
StartActual
Jun 4, 2026
Primary completionEst.
Dec 10, 2030
CompletionEst.
Dec 10, 2030
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07049653
Lead sponsor
AstraZeneca
Collaborators
IQVIA Pty Ltd
Responsible party
Sponsor
First posted
Jul 3, 2025
Start date
Jun 4, 2026
Primary completion
Dec 10, 2030 (estimated)
Completion
Dec 10, 2030 (estimated)
Last update
Sep 18, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion